NIH Director Page NIH Health Information Page NIH Impact NIH Fact Sheets NIH Social Media and Outreach
EurekAlert! - National Institutes of Health  
LINKS

Resources

 

NIH Main

 

NIH Research News

 

Funded News

 
  For News & Research
  NIH Videos
  eColumn: NIH Research Matters
  NIH News in Health
  NIH Fact Sheets
 
  Additional Resources
  NIH Home Page
 

About NIH

  NIH Health Information
  Pub Med
  MedlinePlus
  Clinical trials.gov
  More News and Events Sources
  NIH News and Events, Special Interest
 
  RSS Feed RSS Feed
  Back to EurekAlert!
 

 


Department of Health and Human Services

News from the National Institutes of Health

NIH Research News


Key: Meeting M      Journal J      Funder F

Showing releases 76-84 out of 84.

<< < 1 | 2 | 3 | 4

Public Release: 6-Nov-2014
Lancet
New drug for common liver disease improves liver health
An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the National Institutes of Health. The FLINT study found that people with nonalcoholic steatohepatitis who took obeticholic acid had improved liver health during that period, including decreased inflammation and fat in the liver and decreased body weight versus people receiving a placebo. OCA was also associated with increases in itching and total cholesterol.

Contact: Media Office
NIDDKMedia@mail.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Public Release: 6-Nov-2014
Environmental Health Perspectives
Diversity Outbred mice better predict potential human responses to chemical exposures
A genetically diverse mouse model is able to predict the range of response to chemical exposures that might be observed in human populations, researchers from the National Institutes of Health have found. Like humans, each Diversity Outbred mouse is genetically unique, and the extent of genetic variability among these mice is similar to the genetic variation seen among humans.
NIH/National Institute of Environmental Health Sciences, NIH/National Institute of General Medical Sciences

Contact: Robin Mackar
rmackar@niehs.nih.gov
919-541-0073
NIH/National Institute of Environmental Health Sciences

Public Release: 30-Oct-2014
NIMH creates new unit to support its research domain criteria initiative
A new effort by the National Institutes of Health will facilitate communication among scientists, clinicians, and the public to reframe mental health research, from diagnosis to treatment. The Research Domain Criteria unit was recently established by the National Institute of Mental Health, part of NIH, to support the development of the institute's RDoC initiative.

Contact: Keri Chiodo
NIMHPress@nih.gov
301-443-4536
NIH/National Institute of Mental Health

Public Release: 30-Oct-2014
HIV Research for Prevention (HIV R4P) Conference
Model by NIH grantees explains why HIV prevention dosing differs by sex
A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection via anal sex. This finding helps explain why two large clinical trials testing HIV pre-exposure prophylaxis, or PrEP, in women failed to show efficacy.
NIAID

Contact: Laura S. Leifman
laura.sivitz@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 29-Oct-2014
Nature
Researchers uncover new evidence revealing molecular paths to autism
In the largest study of its kind, researchers used DNA sequencing to uncover dozens of genes that heighten autism risk. Scientists examined more than 14,000 DNA samples from affected children, parents and others, identifying changes in 107 genes that likely contribute to the risk for autism spectrum disorder. The findings provide a better understanding of genetic and cellular changes in pathways and processes possibly involved in ASD, and eventually may help lead to potential therapies.
National Institutes of Health

Contact: Steven Benowitz
steven.benowitz@nih.gov
301-451-8325
NIH/National Human Genome Research Institute

Public Release: 28-Oct-2014
NIH-led study explores prevention of heart disease in HIV-infected people
The National Institutes of Health has launched a clinical trial to assess the effects of aspirin and cholesterol-lowering drugs, or statins, on preventing cardiovascular disease in people with long-term HIV infections. This group, which includes people on antiretroviral therapy as well as 'elite controllers' who can limit the virus without antiretroviral therapy, have a higher risk of developing heart disease and stroke compared to the general population.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Linda Huynh
linda.huynh@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 23-Oct-2014
Cell
TCGA study improves understanding of genetic drivers of thyroid cancer
An analysis of the genomes of nearly 500 papillary thyroid carcinomas -- the most common form of thyroid cancer -- provided new insights into the roles of frequently mutated cancer genes and other alterations driving disease development. The findings also may help improve diagnosis and treatment. Investigators with The Cancer Genome Atlas project identified new molecular subtypes that will help clinicians determine which tumors are more aggressive and which are more likely to respond to certain treatments.
NIH/National Human Genome Research Institute, NIH/National Cancer Institute

Contact: Steven Benowitz
steven.benowitz@nih.gov
301-451-8325
NIH/National Human Genome Research Institute

Public Release: 22-Oct-2014
NIH begins early human clinical trial of VSV Ebola vaccine
Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health's Clinical Center. Researchers at NIAID are conducting the early phase trial to evaluate the vaccine, called VSV-ZEBOV, for safety and its ability to generate an immune system response in healthy adults who are given two intramuscular doses, called a prime-boost strategy. The Walter Reed Army Institute of Research is simultaneously testing the vaccine candidate as a single dose at its Clinical Trials Center.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Kathy Stover
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 20-Oct-2014
Translational Psychiatry
Rapid agent restores pleasure-seeking ahead of other antidepressant action
A drug being studied as a fast-acting mood-lifter restored pleasure-seeking behavior independent of -- and ahead of -- its other antidepressant effectsWithin 40 minutes after a single infusion of ketamine, treatment-resistant depressed bipolar disorder patients experienced a reversal of a key symptom -- loss of interest in pleasurable activities -- which lasted up to 14 days. Brain scans traced the agent's action to boosted activity in areas at the front and deep in the right hemisphere of the brain.
National Institute of Mental Health

Contact: Jules Asher
NIMHpress@nih.gov
301-443-4536
NIH/National Institute of Mental Health

Showing releases 76-84 out of 84.

<< < 1 | 2 | 3 | 4

     
   

HOME    DISCLAIMER    PRIVACY POLICY    CONTACT US
Copyright ©2015 by AAAS, the science society.